Article

Nadir Miyeloproliferatif Bozukluklar: Miyeloproliferatif Neoplazilerin Genetiği

Turkiye Klinikleri J Hematol-Special Topics 06/2013; 6(1):1-12.

ABSTRACT Myeloproliferative neoplasms (MPNs) are clonal hematopoietic disorders originated from genetically transformed stem cells and characterized by myeloid hyperplasia and increased risk for leukemic
transformation. Since the discovery of JAK2-V617F mutation in 2005, our understanding on the molecular and genetic mechanisms underlying the initiation and prognosis of MPNs has been significantly improved. Unlike CML, for which diagnosis and treatment options almost completely rest upon the
BCR-ABL1 fusion gene, pathogenesis of BCR-ABL1-negative MPNs involves highly complex and interrelated processes. It has been shown that mutations in genes involved in cytokine receptor signaling including tyrosine kinases, in RNA splicing and epigenetic machinery as well as in those encoding crucial
transcription factors contribute to the MPN phenotype. Yet, there are many fundamental questions about
the pathogenesis of BCR-ABL1 negative MPNs waiting to be answered. Improvements in
genetic/genomic/epigenetic techniques and widespread use of them will provide an important opportunity in complete identification of somatic mutations, chromosomal rearrangements, and copy number alterations
associated with MPNs

0 0
 · 
0 Bookmarks
 · 
82 Views
  • [show abstract] [hide abstract]
    ABSTRACT: The germline JAK2 haplotype 46/1, tagged by the 'C' allele of single-nucleotide polymorphism (SNP) rs12343867 (C/T), has been associated with JAK2V617F (VF)-positive myeloproliferative neoplasms. SNP rs12343867 was genotyped using bone marrow DNA in 226 consecutive patients with essential thrombocythemia (ET) with concomitant analysis of VF allele burden. The incidence of the 46/1-linked C allele was significantly higher in ET (genotype: CC 15%, CT 52%, TT 33%; C-allele frequency: 41%) than in population controls (P<0.01). Genotype distributions were similar among VF-positive/VF-negative patients (genotype: CC 18/11%, CT 52/53%, TT 30/36%; C-allele: 44/38%; P=0.29). Haplotype 46/1 frequency was remarkably similar when comparing VF-negative patients to those with <10% VF allele burden, but significantly higher in the presence of >10% VF allele burden (genotype: CC 11/13/38%, CT 53/56/38%, TT 36/31/24%; C-allele frequency: 38/41/57%; P<0.01). The clinical features of 46/1-positive and -negative ET were indistinguishable, including blood counts, rate of thrombosis/disease transformation and survival. We conclude that JAK2 haplotype 46/1 confers susceptibility to developing ET independent of VF mutational status and does not seem to further affect the clinical phenotype or prognosis.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 10/2009; 24(1):110-4. · 10.16 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Recently the World Health Organization (WHO), in collaboration with the European Association for Haematopathology and the Society for Hematopathology, published a revised and updated edition of the WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues. The 4th edition of the WHO classification incorporates new information that has emerged from scientific and clinical studies in the interval since the publication of the 3rd edition in 2001, and includes new criteria for the recognition of some previously described neoplasms as well as clarification and refinement of the defining criteria for others. It also adds entities-some defined principally by genetic features-that have only recently been characterized. In this paper, the classification of myeloid neoplasms and acute leukemia is highlighted with the aim of familiarizing hematologists, clinical scientists, and hematopathologists not only with the major changes in the classification but also with the rationale for those changes.
    Blood 05/2009; 114(5):937-51. · 9.06 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The past 7 years have witnessed remarkable progress in our understanding of the genetics of BCR-ABL-negative myeloproliferative neoplasms (MPNs) and has revealed layers of unexpected complexity. Deregulation of JAK2 signaling has emerged as a central feature, but despite having biological activities that recapitulate the cardinal features MPNs in model systems, JAK2 mutations are often secondary events. Several other mutated genes have been identified with a common theme of involvement in the epigenetic control of gene expression. Remarkably, the somatic mutations identified to date do not seem to be acquired in any preferred order, and it is possible that the disease-initiating events remain to be identified. The finding of complex clonal hierarchies in many cases suggests genetic instability that, in principle, may be inherited or acquired. A common haplotype has been identified that is strongly associated with the acquisition of JAK2 mutations, but the cause of relatively high-penetrance familial predisposition to MPNs remains elusive. This review summarizes the established facts relating to the genetics of MPNs, but highlights recent findings and areas of controversy.
    Hematology 01/2011; 2011:208-14. · 1.49 Impact Factor

Full-text

View
49 Downloads
Available from
Jun 12, 2013